z-logo
open-access-imgOpen Access
Down-regulation of LAPTM5 in human cancer cells
Author(s) -
Michelle Nuylan,
Tatsuyuki Kawano,
Johji Inazawa,
Jun Inoue
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.8614
Subject(s) - cancer research , autophagy , cathepsin d , carcinogenesis , programmed cell death , intracellular , cancer cell , biology , cytosol , cell , neuroblastoma , cancer , lung cancer , transmembrane protein , cell culture , medicine , microbiology and biotechnology , apoptosis , pathology , biochemistry , enzyme , genetics , receptor
Lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) is a membrane protein that localizes to intracellular vesicles. It has been previously demonstrated that LAPTM5 expression level is decreased in neuroblastoma (NB) cells, and excessive accumulation of LAPTM5 was shown to induce lysosomal cell death in these cells. However, the pathological expression and role of LAPTM5 in other types of human cancers are largely unknown. Here, we found that LAPTM5 mRNA level is frequently decreased in various cancer cell lines, and its low expression in patients with esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (NSCLC) was significantly correlated with poor prognosis. Furthermore, we showed that overexpression of LAPTM5 in several cancer cells induces lysosomal cell death due to lysosomal destabilization, indicated by leakage of lysosomal cathepsin D into the cytosol as well as impairment of autophagy. These findings suggest that the inactivation of LAPTM5 may contribute to tumorigenesis in a subset of human cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here